Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Angsutararux, Paweorn ^a   Luanpitpong, Sudjit ^a   Issaragrisil, Surapol ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH;

CARDIOMYOCYTES; CARDIOTOXICITY; CHEMOTHERAPEUTIC AGENTS; MODEL DEVELOPMENT; MOLECULAR MECHANISM; PREVENTIVE STRATEGIES; PREVENTIVE TREATMENTS; REACTIVE OXYGEN SPECIES;

CHEMOTHERAPY;

DOXORUBICIN; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT;

APOPTOSIS; AUTOPHAGY; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DEATH; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; HEART CONTRACTION; HEART MUSCLE CELL; HUMAN; HYPERTROPHY; NONHUMAN; OXIDATIVE STRESS; REVIEW; ANIMAL; CARDIAC MUSCLE; DISEASE MODEL; DRUG EFFECTS; HEART; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; HEART; HUMANS; MYOCARDIUM; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84944320607     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/795602     Document Type: Review

References (135)

1. D. W. Kufe, J. F. Holland, and E. Frei, American Cancer Society: Cancer Medicine, BC Decker, Hamilton, Canada, 2003.
2. D. L. Hershman, R. B. McBride, A. Eisenberger, Y. T. Wei, V. R. Grann, and J. S. Jacobson, "Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma," Journal of Clinical Oncology, vol. 26, no. 19, pp. 3159-3165, 2008.
3. L. Gianni, E. Munzone, G. Capri et al. , "Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study," Journal of Clinical Oncology, vol. 13, no. 11, pp. 2688-2699, 1995.
4. E. A. Eisenhauer and J. B. Vermorken, "The taxoids. Comparative clinical pharmacology and therapeutic potential," Drugs, vol. 55, no. 1, pp. 5-30, 1998.
5. A. Giantris, L. Abdurrahman, A. Hinkle, B. Asselin, and S. E. Lipshultz, "Anthracycline-induced cardiotoxicity in children and young adults," Critical Reviews in Oncology/Hematology, vol. 27, no. 1, pp. 53-68, 1998.
6. V. B. Pai andM. C. Nahata, "Cardiotoxicityof chemotherapeutic agents. Incidence, treatment and prevention," Drug Safety, vol. 22, no. 4, pp. 263-302, 2000.
7. E. A. Lefrak, J. Pitha, S. Rosenheim, and J. A. Gottlieb, "A clinicopathologic analysis of adriamycin cardiotoxicity," Cancer, vol. 32, no. 2, pp. 302-314, 1973.
8. V. J. Ferrans, J. R. Clark, J. Zhang, Z.-X. Yu, and E. H. Herman, "Pathogenesis and prevention of doxorubicin cardiomyopathy," Tsitologiya, vol. 39, no. 10, pp. 928-936, 1997.
9. F. L. Medrano, A. S. Munoz, V. S. Sánchez, and J. R. C. Pérez-Herrero, "Cardiotoxicity of 5-fluorouracil: ischemia or myocardial toxicity?" Revista Clnica Española, vol. 201, no. 2, pp. 106-107, 2001.
10. C. Lestuzzi, "Neoplastic pericardial disease: old and current strategies for diagnosis and management," World Journal of Cardiology, vol. 2, no. 9, p. 270, 2010.
11. G. Takemura and H. Fujiwara, "Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management," Progress in Cardiovascular Diseases, vol. 49, no. 5, pp. 330-352, 2007.
12. L. M. Buja, V. J. Ferrans, R. J. Mayer, W. C. Roberts, and E. S. Henderson, "Cardiac ultrastructural changes induced by daunorubicin therapy," Cancer, vol. 32, no. 4, pp. 771-788, 1973.
13. M. E. Billingham, J. W. Mason, M. R. Bristow, and J. R. Daniels, "Anthracycline cardiomyopathy monitored by morphologic changes," Cancer Treatment Reports, vol. 62, no. 6, pp. 865-872, 1978.
14. N. R. Bachur, S. L. Gordon, M. V. Gee, and H. Kon, "NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals," Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 2, pp. 954-957, 1979.
15. V. Berlin and W. A. Haseltine, "Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen,"The Journal of Biological Chemistry, vol. 256, no. 10, pp. 4747-4756, 1981.
16. K. J. A. Davies and J. H. Doroshow, "Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase," Journal of Biological Chemistry, vol. 261, no. 7, pp. 3060-3067, 1986.
17. K. J. M. Schimmel, D. J. Richel, R. B. A. van den Brink, and H. Guchelaar, "Complications of treatment: cardiotoxicity of cytotoxic drugs," Cancer Treatment Reviews, vol. 30, pp. 181-191, 2004.
18. J. H. Doroshow, "Effect of anthracycline antibiotics on oxygen radical formation in rat heart," Cancer Research, vol. 43, no. 2, pp. 460-472, 1983.
19. J. Vásquez-Vivar, P. Martasek, N. Hogg, B. S. S. Masters, K. A. Pritchard Jr. , and B. Kalyanaraman, "Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin," Biochemistry, vol. 36, no. 38, pp. 11293-11297, 1997.
20. D. M. Weinstein, M. J. Mihm, and J. A. Bauer, "Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice," Journal of Pharmacology and Experimental Therapeutics, vol. 294, no. 1, pp. 396-401, 2000.
21. B. Liu, H. Li, H. Qu, and B. Sun, "Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats," Journal of Biochemistry and Molecular Biology, vol. 39, no. 6, pp. 759-765, 2006.
22. J. H. Doroshow, G. Y. Locker, and C. E. Myers, "Enzymatic defenses of themouse heart against reactive oxygen metabolites. Alterations produced by doxorubicin," The Journal of Clinical Investigation, vol. 65, no. 1, pp. 128-135, 1980.
23. M. A. Parker, V. King, and K. P. Howard, "Nuclear magnetic resonance study of doxorubicin binding to cardiolipin containing magnetically oriented phospholipid bilayers," Biochimica et Biophysica Acta, vol. 1514, no. 2, pp. 206-216, 2001.
24. G. M. Hatch and G. McClarty, "Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 5-triphosphate,"The Journal of Biological Chemistry, vol. 271, no. 42, pp. 25810-25816, 1996.
25. E. Goormaghtigh, P. Chatelain, J. Caspers, and J. M. Ruysschaert, "Evidence of a specific complex between adriamycin and negatively-charged phospholipids," Biochimica et Biophysica Acta, vol. 597, no. 1, pp. 1-14, 1980.
26. R. D. Olson, P. S. Mushlin, D. E. Brenner et al. , "Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol," Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 10, pp. 3585-3589, 1988.
27. D. J. Stewart, D. Grewaal, R. M. Green et al. , "Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues," Anticancer Research, vol. 13, pp. 1945-1952, 1993.
28. C. Panis, A. C. S. A. Herrera, V. J. Victorino et al. , "Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy," Breast Cancer Research and Treatment, vol. 133, no. 1, pp. 89-97, 2012.
29. C. F. Thorn, C. Oshiro, S. Marsh et al. , "Doxorubicin pathways: Pharmacodynamics and adverse effects," Pharmacogenetics and Genomics, vol. 21, no. 7, pp. 440-446, 2011.
30. G. Minotti, S. Recalcati, P. Menna, E. Salvatorelli, G. Corna, and G. Cairo, "Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms," Methods in Enzymology, vol. 378, pp. 340-361, 2004.
31. Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. S. Clair, "Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues,"Molecular Interventions, vol. 7, no. 3, pp. 147-156, 2007.
32. E. C. Theil, G. L. Eichorn, and L. Marzili, "Ferritin: structure, function and regulation in iron binding proteins without cofactors and sulfur clusters," Annual Review of Biochemistry, vol. 56, pp. 289-315, 1987.
33. G. Minotti, R. Ronchi, E. Salvatorelli, P. Menna, and G. Cairo, "Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy," Cancer Research, vol. 61, no. 23, pp. 8422-8428, 2001.
34. G. Minotti, G. Cairo, and E. Monti, "Role of iron in anthracycline cardiotoxicity: new tunes for an old song?" The FASEB Journal, vol. 13, no. 2, pp. 199-212, 1999.
35. G. Minotti, S. Recalcati, A. Mordente et al. , "The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium," The FASEB Journal, vol. 12, pp. 541-552, 1998.
36. G. Minotti, C. Mancuso, A. Frustaci et al. , "Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin: Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity," The Journal of Clinical Investigation, vol. 98, no. 3, pp. 650-661, 1996.
37. T. P. A. Devasagayam, J. C. Tilak, K. K. Boloor, K. S. Sane, S. S. Ghaskadbi, and R. D. Lele, "Free radicals and antioxidants in human health: current status and future prospects," Journal of Association of Physicians of India, vol. 52, pp. 794-804, 2004.
38. D. G. Deavall, E. A. Martin, J. M. Horner, and R. Roberts, "Druginduced oxidative stress and toxicity," Journal of Toxicology, vol. 2012, Article ID645460, 13 pages, 2012.
39. A. Sabri, H. H. Hughie, and P. A. Lucchesi, "Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes," Antioxidants and Redox Signaling, vol. 5, no. 6, pp. 731-740, 2003.
40. D. A. Siwik, J. D. Tzortzis, D. R. Pimental et al. , "Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro," Circulation Research, vol. 85, no. 2, pp. 147-153, 1999.
41. S. H. Kwon, D. R. Pimentel, A. Remondino, D. B. Sawyer, andW. S. Colucci, "H2O2 regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways," Journal of Molecular and Cellular Cardiology, vol. 35, no. 6, pp. 615-621, 2003.
42. D. A. Siwik, P. J. Pagano, andW. S. Colucci, "Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts,"The American Journal of Physiology-Cell Physiology, vol. 280, no. 1, pp. C53-C60, 2001.
43. N. S. Dhalla, R. M. Temsah, and T. Netticadan, "Role of oxidative stress in cardiovascular diseases," Journal of Hypertension, vol. 18, no. 6, pp. 655-673, 2000.
44. C. J. Miranda, H. Makui, R. J. Soares et al. , "Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin," Blood, vol. 102, no. 7, pp. 2574-2580, 2003.
45. T. Sim?unek, M. Sterba, O. Popelová, M. Adamcová, R. Hrdina, and V. Gersi, "Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron," Pharmacological Reports, vol. 61, no. 1, pp. 154-171, 2009.
46. N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill, "Hypertrophy of the heart: A new therapeutic target?" Circulation, vol. 109, no. 13, pp. 1580-1589, 2004.
47. S. Mouli, G. R. Nanayakkara, R. Fu et al. , "The role of frataxin in doxorubicin-mediated cardiac hypertrophy," The FASEB Journal, vol. 28, no. 1, supplement 648. 6, 2014.
48. T. C. Karagiannis, A. J. E. Lin, K. Ververis et al. , "Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes," Aging, vol. 2, no. 10, pp. 659-668, 2010.
49. J.-M. Li, N. P. Gall, D. J. Grieve, M. Chen, and A. M. Shah, "Activation of NADPH oxidase during progression of cardiac hypertrophy to failure," Hypertension, vol. 40, no. 4, pp. 477-484, 2002.
50. M. O. Date, T. Morita,N. Yamashita et al. , "The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model," Journal of the American College of Cardiology, vol. 39, no. 5, pp. 907-912, 2002.
51. Y. Higuchi, K. Otsu, K. Nishida et al. , "Involvement of reactive oxygen species-mediated NF-B activation in TNF-induced cardiomyocyte hypertrophy," Journal of Molecular and Cellular Cardiology, vol. 34, no. 2, pp. 233-240, 2002.
52. D. R. Pimentel, J. K. Amin, L. Xiao et al. , "Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes," Circulation Research, vol. 89, no. 5, pp. 453-460, 2001.
53. S. Hirotani, K. Otsu, K. Nishida et al. , "Involvement of nuclear factor-B and apoptosis signal-regulating kinase 1 in G-proteincoupled receptor agonist-induced cardiomyocyte hypertrophy," Circulation, vol. 105, no. 4, pp. 509-515, 2002.
54. K. Nakamura, K. Fushimi, H. Kouchi et al. , "Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II," Circulation, vol. 98, no. 8, pp. 794-799, 1998.
55. Y. Izumiya, S. Kim, Y. Izumi et al. , "Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling," Circulation Research, vol. 93, no. 9, pp. 874-883, 2003.
56. K. E. Merten, Y. Jiang,W. Feng, andY. J. Kang, "Calcineurinactivation is not necessary for doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-akt pathway," Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 2, pp. 934-940, 2006.
57. X. Sun, Z. Zhou, and Y. J. Kang, "Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart," Cancer Research, vol. 61, no. 8, pp. 3382-3387, 2001.
58. A. V. Spreeuwel, N. Bax, and C. Bouten, "The relevance of extracellular matrix structure and composition in engineering the diseased cardiac microenvironment," Tissue Engineering & Modeling, vol. 2, no. 1, 2014.
59. M. L. McCain, H. Yuan, F. S. Pasqualini, P. H. Campbell, and K. K. Parker, "Matrix elasticity regulates the optimal cardiac myocyte shape for contractility," American Journal of Physiology-Heart and Circulatory Physiology, vol. 306, no. 11, pp. H1525-H1539, 2014.
60. A. Goetzenich, N. Hatam, A. Zernecke et al. , "Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig," Journal of Heart and Lung Transplantation, vol. 28, no. 10, pp. 1087-1093, 2009.
61. D. Nikitovic, I. Juranek, M. F. Wilks, M. Tzardi,A. Tsatsakis, and G. N. Tzanakakis, "Anthracycline-dependent cardiotoxicity and extracellular matrix remodeling," CHEST Journal, vol. 146, no. 4, p. 1123, 2014.
62. D. L. Mann and F. G. Spinale, "Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds," Circulation, vol. 98, no. 17, pp. 1699-1702, 1998.
63. F. G. Spinale, M. L. Coker, C. V. Thomas, J. D. Walker, R. Mukherjee, and L. Hebbar, "Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function," Circulation Research, vol. 82, no. 4, pp. 482-495, 1998.
64. M. Ivanová, I. Dovinová, L. Okruhlicová et al. , "Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats," Acta Pharmacologica Sinica, vol. 33, no. 4, pp. 459-469, 2012.
65. K. Kizaki, R. Ito, M. Okada et al. , "Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatmentwith doxorubicin in mice," Pharmacological Research, vol. 53, no. 4, pp. 341-346, 2006.
66. P. Bai, J. Mabley, L. Liaudet, L. Virág, C. Szabó, and P. Pacher, "Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity," Oncology Reports, vol. 11, no. 2, pp. 505-508, 2004.
67. P. Spallarossa, P. Altieri, S. Garibaldi et al. , "Matrix metalloproteinase-2 and-9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase," Cardiovascular Research, vol. 69, no. 3, pp. 736-745, 2006.
68. Y. Zhao, D. McLaughlin, E. Robinson et al. , "Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy," Cancer Research, vol. 70, no. 22, pp. 9287-9297, 2010.
69. P. Mukhopadhyay, M. Rajesh, S. Bátkai et al. , "Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro," The American Journal of Physiology: Heart and Circulatory Physiology, vol. 296, no. 5, pp. H1466-H1483, 2009.
70. T. Okamoto, T. Akaike, T. Sawa, Y. Miyamoto, A. van der Vliet, and H. Maeda, "Activation of matrix metalloproteinases by peroxynitrite-induced protein s-glutathiolation via disulfide soxide formation,"The Journal of Biological Chemistry, vol. 276, no. 31, pp. 29596-29602, 2001.
71. H. Ito, S. C. Miller, M. E. Billingham et al. , "Dexorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro," Proceedings of theNational Academy of Sciences of the United States of America, vol. 87, no. 11, pp. 4275-4279, 1990.
72. R. Jeyaseelan, C. Poizat, H.-Y. Wu, and L. Kedes, "Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes," Journal of Biological Chemistry, vol. 272, no. 9, pp. 5828-5832, 1997.
73. Y. Kim, A.-G. Ma, K. Kitta et al. , "Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiacmyocyte apoptosis,"Molecular Pharmacology, vol. 63, no. 2, pp. 368-377, 2003.
74. A. Aries, P. Paradis, C. Lefebvre, R. J. Schwartz, and M. Nemer, "Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 18, pp. 6975-6980, 2004.
75. S.-S. Takahashi, M. A. Denvir, L. Harder et al. , "Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in 'chemically-skinned' rabbit ventricular trabeculae," Japanese Journal of Pharmacology, vol. 76, no. 4, pp. 405-413, 1998.
76. D. A. Dodd, J. B. Atkinson, R. D. Olson et al. , "Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model," The Journal of Clinical Investigation, vol. 91, no. 4, pp. 1697-1705, 1993.
77. J. I. Kourie, "Interaction of reactive oxygen species with ion transport mechanisms," The American Journal of Physiology-Cell Physiology, vol. 275, no. 1, pp. C1-C24, 1998.
78. C. Mylonas and D. Kouretas, "Lipid peroxidation and tissue damage," In Vivo, vol. 13, no. 3, pp. 295-309, 1999.
79. M. Arai, K. Tomaru, T. Takizawa et al. , "Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits," Journal of Molecular and Cellular Cardiology, vol. 30, no. 2, pp. 243-254, 1998.
80. P. Kaplan, E. Babusikova, J. Lehotsky, and D. Dobrota, "Free radical-induced protein modification and inhibition of Ca2+-ATPase of cardiac sarcoplasmic reticulum," Molecular and Cellular Biochemistry, vol. 248, no. 1-2, pp. 41-47, 2003.
81. M. Arai, A. Yoguchi, T. Takizawa et al. , "Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca2+-ATPase gene transcription," Circulation Research, vol. 86, no. 1, pp. 8-14, 2000.
82. A. V. Zima and L. A. Blatter, "Redox regulation of cardiac calcium channels and transporters," Cardiovascular Research, vol. 71, no. 2, pp. 310-321, 2006.
83. L. Xu, J. P. Eu, G. Meissner, and J. S. Stamler, "Activation of the cardiac calcium release channel (Ryanodoine receptor) by poly-S-nitrosylation," Science, vol. 279, no. 5348, pp. 234-237, 1998.
84. S. R. M. Holmberg and A. J. Williams, "Patterns of interaction between anthraquinone drugs and the calcium-release channel fromcardiac sarcoplasmic reticulum," Circulation Research, vol. 67, no. 2, pp. 272-283, 1990.
85. K. Saeki, I. Obi, N. Ogiku, M. Shigekawa, T. Imagawa, and T. Matsumoto, "Doxorubicin directly binds to the cardiac-type ryanodine receptor," Life Sciences, vol. 70, no. 20, pp. 2377-2389, 2002.
86. E. C. Keung, L. Toll, M. Ellis, and R. A. Jensen, "L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations," Journal of Clinical Investigation, vol. 87, no. 6, pp. 2108-2113, 1991.
87. P. Caroni, F. Villani, and E. Carafoli, "The cardiotoxic antibiotic doxorubicin inhibits the Na+/Ca2+ exchange of dog heart sarcolemmal vesicles," FEBS Letters, vol. 130, no. 2, pp. 184-186, 1981.
88. R. J. Boucek Jr. , R. D. Olson, D. E. Brenner, E. M. Ogunbunmi, M. Inui, and S. Fleischer, "Themajor metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: A correlative study of cardiac muscle with isolated membrane fractions,"The Journal of Biological Chemistry, vol. 262, no. 33, pp. 15851-15856, 1987.
89. I. N. Lavrik and P. H. Krammer, "Regulation of CD95/Fas signaling at the DISC," Cell Death and Differentiation, vol. 19, no. 1, pp. 36-41, 2012.
90. A. G. Porter and R. U. Jänicke, "Emerging roles of caspase-3 in apoptosis," Cell Death and Differentiation, vol. 6, no. 2, pp. 99-104, 1999.
91. C. Kantari and H. Walczak, "Caspase-8 and Bid: caught in the act between death receptors and mitochondria," Biochimica et Biophysica Acta, vol. 1813, no. 4, pp. 558-563, 2011.
92. T. Kaufmann, A. Strasser, and P. J. Jost, "Fas death receptor signalling: roles of Bid and XIAP," Cell Death & Differentiation, vol. 19, no. 1, pp. 42-50, 2012.
93. F. Van Herreweghe, N. Festjens, W. Declercq, and P. Vandenabeele, "Tumor necrosis factor-mediated cell death: To break or to burst, that's the question," Cellular and Molecular Life Sciences, vol. 67, no. 10, pp. 1567-1579, 2010.
94. H. Wajant and P. Scheurich, "TNFR1-induced activation of the classical NF-B pathway,"The FEBS Journal, vol. 278, no. 6, pp. 862-876, 2011.
95. D. N. Dhanasekaran and E. P. Reddy, "JNK signaling in apoptosis," Oncogene, vol. 27, no. 48, pp. 6245-6251, 2008.
96. J. K. Brunelle and A. Letai, "Control ofmitochondrial apoptosis by the Bcl-2 family," Journal of Cell Science, vol. 122, no. 4, pp. 437-441, 2009.
97. D. B. Sawyer, X. Peng, B. Chen, L. Pentassuglia, and C. C. Lim, "Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?" Progress in Cardiovascular Diseases, vol. 53, no. 2, pp. 105-113, 2010.
98. S. Kotamraju, E. A. Konorev, J. Joseph, and B. Kalyanaraman, "Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species," The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33585-33592, 2000.
99. L. Wang, W. Ma, R. Markovich, J.-W. Chen, and P. H. Wang, "Regulation of cardiomyocyte apoptotic signaling by insulinlike growth factor I," Circulation Research, vol. 83,no. 5, pp. 516-522, 1998.
100. O. J. Arola, A. Saraste, K. Pulkki,M. Kallajoki,M. Parvinen, and L. M. Voipio-Pulkki, "Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis," Cancer Research, vol. 60, no. 7, pp. 1789-1792, 2000.
101. R. H. Houtkooper and F. M. Vaz, "Cardiolipin, the heart of mitochondrial metabolism," Cellular and Molecular Life Sciences, vol. 65, no. 16, pp. 2493-2506, 2008.
102. C. Thollon, J. P. Iliou, C. Cambarrat, F. Robin, and J. P. Vilaine, "Nature of the cardiomyocyte injury induced by lipid hydroperoxides," Cardiovascular Research, vol. 30, no. 5, pp. 648-655, 1995.
103. N. Rathore, S. John, M. Kale, and D. Bhatnagar, "Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues," Pharmacological Research, vol. 38, no. 4, pp. 297-303, 1998.
104. T. Hemnani and M. S. Parihar, "Reactive oxygen species and oxidative DNA damage," Indian Journal of Physiology and Pharmacology, vol. 42, no. 4, pp. 440-452, 1998.
105. N. Suematsu, H. Tsutsui, J. Wen et al. , "Oxidative stressmediates tumor necrosis factor-induced mitochondrial DNA damage and dysfunction in cardiac myocytes," Circulation, vol. 107, no. 10, pp. 1418-1423, 2003.
106. L. Costa, V. Malatesta, F. Morazzoni, R. Scotti, E. Monti, and L. Paracchini, "Direct detection of paramagnetic species in adriamycin perfused rat hearts," Biochemical and Biophysical Research Communications, vol. 153, no. 1, pp. 275-280, 1988.
107. P. K. Singal and G. N. Pierce, "Adriamycin stimulates lowaffinity Ca2+ binding and lipid peroxidation but depresses myocardial function," American Journal of Physiology-Heart andCirculatory Physiology, vol. 250, no. 3, pp. H419-H425, 1986.
108. P. K. Singal,R. J. Segstro,R. P. Singh, and M. J. Kutryk, "Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy," Canadian Journal of Cardiology, vol. 1, no. 2, pp. 139-147, 1985.
109. J. Serrano, C. M. Palmeira,D. W. Kuehl, andK. B. Wallace, "Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration," Biochimica et Biophysica Acta, vol. 1411, no. 1, pp. 201-205, 1999.
110. R. D. Olson, J. S. MacDonald, C. J. van Boxtel et al. , "Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin," Journal of Pharmacology and Experimental Therapeutics, vol. 215, no. 2, pp. 450-454, 1980.
111. G. C. Pereira, A. M. Silva, C. V. Diogo, F. S. Carvalho, P. Monteiro, and P. J. Oliveira, "Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol," Current Pharmaceutical Design, vol. 17, no. 20, pp. 2113-2129, 2011.
112. A. L. Odom, C. A. Hatwig, J. S. Stanley, and A. M. Benson, "Biochemical determinants of adriamycin toxicity in mouse liver, heart and intestine," Biochemical Pharmacology, vol. 43, no. 4, pp. 831-836, 1992.
113. H. M. Abd El-Gawad and M. M. El-Sawalhi, "Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine," Journal of Biochemical and Molecular Toxicology, vol. 18, no. 2, pp. 69-77, 2004.
114. D. C. Wallace, "Mitochondrial defects in cardiomyopathy and neuromuscular disease," American Heart Journal, vol. 139, no. 2, pp. S70-S85, 2000.
115. C. D. Venkatakrishnan, A. K. Tewari, L. Moldovan et al. , "Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 291, no. 6, pp. H2680-H2691, 2006.
116. J. Ghosh, J. Das, P. Manna, and P. C. Sil, "The protective role of arjunolic acid against doxorubicin induced intracellular ROS dependent JNK-p38 and p53-mediated cardiac apoptosis," Biomaterials, vol. 32, no. 21, pp. 4857-4866, 2011.
117. J. Nitobe, S. Yamaguchi, M. Okuyama et al. , "Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes," Cardiovascular Research, vol. 57, no. 1, pp. 119-128, 2003.
118. Y.-C. Lien, T. Noel, H. Liu, A. J. Stromberg, K.-C. Chen, and D. K. St. Clair, "Phospholipase C-1 is a critical target for tumor necrosis factor receptor-mediated protection against adriamycin-induced cardiac injury," Cancer Research, vol. 66, no. 8, pp. 4329-4338, 2006.
119. Y. Nakamura, K. Kanemaru, R. Kojima et al. , "Simultaneous loss of phospholipase C1 and phospholipase C3 causes cardiomyocyte apoptosis and cardiomyopathy," Cell Death and Disease, vol. 5, no. 5. article e1215, 2014.
120. A. C. Childs, S. L. Phaneuf, A. J. Dirks, T. Phillips, and C. Leeuwenburgh, "Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio," Cancer Research, vol. 62, no. 16, pp. 4592-4598, 2002.
121. M. Ueno, Y. Kakinuma, K.-I. Yuhki et al. , "Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo," Journal of Pharmacological Sciences, vol. 101, no. 2, pp. 151-158, 2006.
122. L. Lu, W. Wu, J. Yan, X. Li, H. Yu, and X. Yu, "Adriamycininduced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure," International Journal of Cardiology, vol. 134, no. 1, pp. 82-90, 2009.
123. P. Dimitrakis, M.-I. Romay-Ogando, F. Timolati, T. M. Suter, and C. Zuppinger, "Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes,"Cell and Tissue Research, vol. 350, no. 2, pp. 361-372, 2012.
124. T. Kawaguchi, G. Takemura, H. Kanamori et al. , "Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes," Cardiovascular Research, vol. 96, no. 3, pp. 456-465, 2012.
125. S. Kobayashi, P. Volden, D. Timm, K. Mao, X. Xu, and Q. Liang, "Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death," The Journal of Biological Chemistry, vol. 285, no. 1, pp. 793-804, 2010.
126. A. J. Smuder, A. N. Kavazis, K. Min, and S. K. Powers, "Doxorubicin-induced markers of myocardial autophagic signaling in sedentary and exercise trained animals," Journal of Applied Physiology, vol. 115, no. 2, pp. 176-185, 2013.
127. Y. Zhang, C. Meng, X. Zhang et al. , "Ophiopogonin D attenuates doxorubicin-induced autophagic cell death by relieving mitochondrial damage in vitro and in vivo," The Journal of Pharmacology & Experimental Therapeutics, vol. 352, no. 1, pp. 166-174, 2014.
128. X. Xu, K. Chen, S. Kobayashi, D. Timm, and Q. Liang, "Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy," The Journal of Pharmacology and ExperimentalTherapeutics, vol. 341, no. 1, pp. 183-195, 2012.
129. B. J. N. Sishi, B. Loos, J. van Rooyen, and A.-M. Engelbrecht, "Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity," Biochemical Pharmacology, vol. 85, no. 1, pp. 124-134, 2013.
130. G. N. Hortobagyi, H.-Y. Yap, S. W. Kau et al. , "A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer," American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 12, no. 1, pp. 57-62, 1989.
131. R. B. Weiss, "The anthracyclines: will we ever find a better doxorubicin?" Seminars in Oncology, vol. 19, no. 6, pp. 670-686, 1992.
132. L. A. Smith,V. R. Cornelius, C. J. Plummer et al. , "Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic reviewandmeta-analysis of randomised controlled trials,"BMC Cancer, vol. 10, article 337, 2010.
133. A. A. Gabizon, "Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet," Clinical Cancer Research, vol. 7, no. 2, pp. 223-225, 2001.
134. C. K. Tebbi, W. B. London, D. Friedman et al. , "Dexrazoxaneassociated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease," Journal of Clinical Oncology, vol. 25, no. 5, pp. 493-500, 2007.
135. S. M. Swain, F. S. Whaley, M. C. Gerber et al. , "Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer," Journal of ClinicalOncology, vol. 15,no. 4, pp. 1318-1332, 1997.